CLINICAL RESEARCH: HEART FAILURE AND BNP
Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart
Paul R. Forfia, MD2,
Myung Lee, MS,
Richard S. Tunin, MS,
Mobusher Mahmud, MD,
Hunter C. Champion, MD, PhD and
David A. Kass, MD1,*
Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Manuscript received May 2, 2006;
revised manuscript received August 18, 2006,
accepted August 30, 2006.
* Reprint requests and correspondence: Dr. David A. Kass, Division of Cardiology, Johns Hopkins Medical Institutions, Ross 835, 720 Rutland Avenue, Baltimore, Maryland 21205. (Email: dkass{at}jhmi.edu).
Objectives: The aim of this work was to test whether acute phosphodiesterase 5 (PDE5) inhibition via sildenafil (SIL) mimics and/or potentiates cardiorenal effects of exogenous natriuretic peptide (NP) infusion.
Background: Heart failure (HF) is often accompanied by elevated NP secretion yet blunted responsiveness. Such NP resistance may, in part, relate to increased cyclic guanosine monophosphate (cGMP) catabolism by PDE5.
Methods: Dogs (n = 7) were studied before and after tachypacing-induced HF. Animals received 30-min infusion of B-type natriuretic peptide (BNP) (2 µg/kg bolus, 0.02 µg/kg/min), and on a separate day SIL (1 mg/kg, intravenous), followed by BNP (SIL + BNP). Phosphodiesterase 5 activity was measured in lung, vasculature, and kidney.
Results: At baseline (non-failing), BNP lowered central venous, pulmonary capillary wedge, diastolic, mean pulmonary artery, and mean arterial pressure. Sildenafil had no effects, and SIL + BNP was similar to BNP alone. In contrast, SIL lowered these pressures similarly to BNP in dogs with HF, and SIL + BNP was additive in further reducing pulmonary pressures over BNP alone. Plasma cGMP/plasma BNP ratio was markedly reduced with HF, indicating NP resistance. Sildenafil plus BNP increased this ratio in HF, but had no effect in non-failing animals. Sildenafil had no independent diuretic/natriuretic effects nor did it enhance BNP effects under baseline or HF conditions. In HF, PDE5 activity was significantly increased in the systemic and pulmonary vasculature and in the kidney.
Conclusions: The PDE5 activity in systemic and pulmonary vasculature increases in HF rendering hemodynamic responses to PDE5 inhibition identical to those from BNP infusion. Natriuretic peptide desensitization in HF relates, in part, to increased PDE5 activity, supporting a therapeutic role for PDE5 inhibition.
|
Abbreviations and Acronyms
| | ANP = atrial natriuretic peptide | | BNP = B-type natriuretic peptide | | cGMP = cyclic guanosine monophosphate | | dPAP = diastolic pulmonary artery pressure | | HF = heart failure | | LV = left ventricle/ventricular | | LVEF = left ventricular ejection fraction | | mPAP = mean pulmonary artery pressure | | NP = natriuretic peptide | | PDE5 = phosphodiesterase type-5 | | SIL = sildenafil | | SV = stroke volume |
|
Related Article
-
Heart Failure: A State of Brain Natriuretic Peptide Deficiency or Resistance or Both!
- Horng H. Chen
J. Am. Coll. Cardiol. 2007 49: 1089-1091.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
V. Melenovsky, H. Al-Hiti, L. Kazdova, A. Jabor, P. Syrovatka, I. Malek, J. Kettner, and J. Kautzner
Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil.
J. Am. Coll. Cardiol.,
August 11, 2009;
54(7):
595 - 600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. H. Chen, A. Cataliotti, J. A. Schirger, F. L. Martin, L. K. Harstad, and J. C. Burnett Jr
Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure.
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
1302 - 1308.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Lourenco, J. P. Araujo, A. Azevedo, A. Ferreira, and P. Bettencourt
The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure
Eur J Heart Fail,
February 1, 2009;
11(2):
185 - 190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pokreisz, S. Vandenwijngaert, V. Bito, A. Van den Bergh, I. Lenaerts, C. Busch, G. Marsboom, O. Gheysens, P. Vermeersch, L. Biesmans, et al.
Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice
Circulation,
January 27, 2009;
119(3):
408 - 416.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K. L. Gabrielson, E. Takimoto, and D. A. Kass
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.
J. Am. Coll. Cardiol.,
January 13, 2009;
53(2):
207 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo
Cardiorenal Syndrome
J. Am. Coll. Cardiol.,
November 4, 2008;
52(19):
1527 - 1539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Guazzi
Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure
Circ Heart Fail,
November 1, 2008;
1(4):
272 - 280.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nagayama, M. Zhang, S. Hsu, E. Takimoto, and D. A. Kass
Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil
J. Pharmacol. Exp. Ther.,
August 1, 2008;
326(2):
380 - 387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. B. Daniels and A. S. Maisel
Natriuretic Peptides
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2357 - 2368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Kass, H. C. Champion, and J. A. Beavo
Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation
Circ. Res.,
November 26, 2007;
101(11):
1084 - 1095.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Byrne, R. H. Helm, S. Daya, N. F. Osman, H. R. Halperin, R. D. Berger, D. A. Kass, and A. C. Lardo
Diminished Left Ventricular Dyssynchrony and Impact of Resynchronization in Failing Hearts With Right Versus Left Bundle Branch Block
J. Am. Coll. Cardiol.,
October 9, 2007;
50(15):
1484 - 1490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Kass, E. Takimoto, T. Nagayama, and H. C. Champion
Phosphodiesterase regulation of nitric oxide signaling
Cardiovasc Res,
July 15, 2007;
75(2):
303 - 314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. H. Chen
Heart Failure: A State of Brain Natriuretic Peptide Deficiency or Resistance or Both!
J. Am. Coll. Cardiol.,
March 13, 2007;
49(10):
1089 - 1091.
[Full Text]
[PDF]
|
 |
|
|